1 / 21

SLIT: dealing with trouble, doing it right.

Gain insight into allergy and allergen immunotherapy at Allergy School. FDA Committee votes to approve SLIT treatments.

lrichardson
Download Presentation

SLIT: dealing with trouble, doing it right.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SLIT: dealing with trouble, doing it right. Allergy SchoolAn Insight into Allergy and Allergen Immunotherapy11 – 13 September 2014Athens, Greece Giovanni B Pajno MD Professor of Pediatrics Department of Pediatrics – Allergy Unit University of Messina Italy

  2. FDA Committee Votes to Approve SLIT Treatments Last month, the Allergenic Products Advisory Committee (APAC) of the Food and Drug Administration (FDA) met and voted that the available safety and efficacy data support approval of two sublingual allergy immunotherapy (AIT) products. One is a grass pollen AIT tablet developed by Stallergenes and the other is Merck’s grass pollen AIT tablet. The APAC voted 9-1 regarding approval of the Stallergenes tablet and 9-0 regarding the Merck tablet. The FDA will need to give final approval, but it usually follows the advice of its advisory committees. AAAAI President Linda Cox, MD, FAAAAI, said in an email to members: “There are no FDA-approved forms of sublingual AIT currently available here in the United States, so these products would be the first licensed therapies of their kind. It’s worth noting that the committee felt very strongly about including language in the prescribing instructions for both products that recommended the patient has autoinjectable epinephrine in the event of a severe allergic reaction." Dr. Cox also discusses the news in this month's President's Message. More information, including a webcast of the meetings, is available from the FDA website

  3. SLIT 1. Early intervention 2. Long lasting effect 3. Adherence

  4. SLIT 1. Early intervention 2. Long lasting effect 3. Adherence

  5. G.B. Pajno Persistent Allergic Diseases Persistent Wheeze Atopic Dermatitis Hay Fever Food Allergy TH2 polarized Immunity Food Allergens Inhalant Allergens Allergens Exposure SLIT Birth Increasing post-natal age Hampering the progression and worsening of IgE mediated disorders J Allergy Clin Immunol 2007;119:796-801.

  6. (Di Rienzo V et al. Clin Exp Allergy 2003;33:206-210)

  7. Specific immunotherapy: beyond the clinical scores Passalacqua G Annals of Allergy 2011;107:401-406 Figure 1. Percentage of children in the immunotherapy and control groups who developed asthma after 3 years, in the 3 available trials. In the study by Marogna et al,37 the development of persistent asthma was assessed

  8. SLIT 1. Early intervention 2. Long lasting effect 3. Adherence

  9. - SLIT

  10. SLIT 1. Early intervention 2. Long lasting effect 3. Adherence

  11. J Allergy Clin Immunol. 2005;116:1380-1

  12. J Allergy Clin Immunol. 2005;116:1380-1

  13. Allergen immunotherapy practice parameter , JACI 2010

  14. Discontinuation 52% three y. old 18% four y. " 13% five y. "

  15. CONCLUSION

  16. Exp Review Clin Immunol in press Pajno G et al.

More Related